Endosomal sorting complexes required for transport-III (ESCRT-III) subunits cycle between two states: soluble monomers and higher-order assemblies that bind and remodel membranes during endosomal vesicle formation, midbody abscission and enveloped virus budding. Here we show that the N-terminal core domains of increased sodium tolerance-1 (IST1) and charged multivesicular body protein-3 (CHMP3) form equivalent four-helix bundles, revealing that IST1 is a previously unrecognized ESCRT-III family member. IST1 and its ESCRT-III binding partner, CHMP1B, both form higher-order helical structures in vitro, and IST1-CHMP1 interactions are required for abscission. The IST1 and CHMP3 structures also reveal that equivalent downstream a5 helices can fold back against the core domains. Mutations within the CHMP3 core-a5 interface stimulate the protein's in vitro assembly and HIV-inhibition activities, indicating that dissociation of the autoinhibitory a5 helix from the core activates ESCRT-III proteins for assembly at membranes.
The endosomal sorting complexes required for transport (ESCRT) pathway functions in a series of important membrane-remodeling processes, including multivesicular body vesicle formation at endosomal membranes, enveloped virus budding from the plasma membrane and midbody abscission during cytokinesis (reviewed in refs. [1] [2] [3] [4] . In performing these functions, ESCRT components cycle between two different states: an inactive state, in which they are dispersed throughout the cytoplasm, and an active state, in which they are recruited to specific membranes by upstream adaptor proteins that induce tight membrane binding and component assembly. ESCRT recruitment and assembly ultimately lead to membrane fission, producing endosomal vesicles, budded viruses or daughter cells. The ESCRT pathway is therefore apparently a mobile machine that can be recruited to different membranes to help mediate membrane remodeling and fission.
Most of the approximately 30 proteins of the human ESCRT pathway function as components of one of five different complexes (termed the ESCRT-0-III and VPS4 complexes). These complexes are recruited sequentially to sites of action, with each successive complex recruiting and activating downstream complexes for membrane association and assembly [1] [2] [3] [4] . Recent studies have revealed that subunits of the late-acting ESCRT-III complex can form rings, helical filaments and tubes in vitro and in vivo. Thus, ESCRT-III complexes may form 'collars' within the cytoplasm-filled necks of membrane vesicles and tubules that can constrict the neck and promote membrane fission [5] [6] [7] [8] [9] [10] .
Variants of this general model suggest that one specific subset of ESCRT-III proteins, those of the CHMP4/Snf7p (Snf7p is a yeast CHMP4 homolog) family, may create an encircling ring or spiral, and the other ESCRT-III proteins serve primarily to nucleate and cap the CHMP4 filament [8] [9] [10] . ESCRT-III proteins also recruit VPS4 ATPases and induce them to assemble into active complexes. Enzyme recruitment and activation are further promoted by the accessory factors IST1 [11] [12] [13] [14] and LIP5 (Vtalp in yeast) [1] [2] [3] [4] , both of which can bind ESCRT-III and VPS4 proteins. Once assembled, VPS4 uses the energy of ATP hydrolysis to release the assembled ESCRT-III machinery back into the cytoplasm, thereby allowing multiple rounds of membrane deformation and fission 10 .
The 11 known human ESCRT-III-like proteins can be divided into seven different families, six of which (CHMP1-6) correspond to the six ESCRT-III-like proteins of Saccharomyces cerevisiae. Most ESCRT-III proteins can form both homo-and hetero-oligomers and can pair preferentially at membrane sites of action (for example, CHMP4-CHMP6 and CHMP2-CHMP3) 6, 15 . ESCRT-III proteins vary considerably in primary sequence, but all share common N-terminal core domains of B150 residues. The core domain of one ESCRT-III protein, CHMP3 , has been crystallized and shown to form a four-helix bundle 16 . The longer first two helices form an extended hairpin, and the shorter two helices pack at the open end of the hairpin. Sequences located beyond the helical core have autoinhibitory activities, and there is now considerable biochemical and genetic evidence that these downstream sequences prevent premature membrane binding and assembly 6, [16] [17] [18] [19] [20] [21] . Downstream sequence elements also bind various late-acting ESCRT factors, including ALIX 22 and a series of microtubule-interacting and transport (MIT) domaincontaining proteins and enzymes such as ubiquitin hydrolases (for example, AMSH and UBPY) 23, 24 , proteases (calpain 7) 25, 26 , ATPases (Spastin and VPS4 proteins) 21, [27] [28] [29] [30] and ATPase activators (LIP5 (Vtalp)) [31] [32] [33] . Different ESCRT-III subunits have distinct binding partner specificities, helping to explain the need for so many different ESCRT-III proteins. IST1 is a recently identified, late-acting ESCRT pathway factor that binds LIP5, VPS4 and CHMP1 (Did2p in yeast) [11] [12] [13] [14] . The precise function(s) of IST1 are not well understood and, indeed, IST1 can exert both positive [11] [12] [13] [14] and negative 12 effects on ESCRT pathway functions. Yeast Ist1p has synthetic interactions with the Vta1p-Vps60p (LIP5-CHMP5) complex in endosomal protein-sorting reactions, implying that Ist1p functions in the formation of multivesicular bodies (MVB), albeit in a non-essential role 12, 13 . Human IST1 localizes to midbodies, and its depletion inhibits abscission but not HIV budding 11, 14 . IST1 proteins therefore seem to have important roles in cytokinesis, auxiliary roles in endosomal protein sorting and no essential role in HIV budding. Biochemical and secondarystructure analyses indicate that IST1 is composed of a helical N-terminal domain (residues 1-189, here termed IST1 NTD , but also called the 'ELYC' domain after a conserved tetrapeptide sequence 12 ), C-terminal MIT-interacting motifs (MIM) (residues 321-366) that can bind cooperatively to the MIT domains of VPS4 (refs. 11,14) and a central linker region that is predicted to lack persistent secondary structure (residues B190-320) 11, 14 .
Extensive structural and biochemical analyses have revealed many of the relevant molecular interactions that allow different ESCRT components to associate with one another, with phosphatidylinositol-3-phosphate (PI(3)P)-containing membranes and with ubiquitylated protein cargoes [1] [2] [3] [4] . In contrast, the mechanisms that regulate ESCRT pathway assembly and disassembly are much less well understood. Here we have determined crystal structures of the human IST1 and CHMP3 proteins. Furthermore, we have performed complementary biochemical analyses that characterize the functional importance of the IST1-CHMP1 binding interaction in cytokinesis, and we suggest how ESCRT-III proteins can switch between their inactive, soluble states and their active, membrane-bound assemblies.
RESULTS

Characterization of recombinant CHMP3 and IST1 proteins
We developed methods for expressing and purifying recombinant human IST1 and CHMP3 proteins for structural and biochemical studies. Full-length CHMP3 and an N-terminally truncated construct (CHMP3 ) were both monomeric in solution, as analyzed by equilibrium sedimentation (Fig. 1a,b ), in good agreement with a previous report 16 . Full-length IST1 was also monomeric under highionic-strength conditions (4300 mM NaCl) 11 , but aggregated at lower ionic strength. The purified N-terminal domain of IST1 (IST1 NTD ) behaved similarly to the full-length protein in that it was also monomeric under high-ionic-strength conditions ( Fig. 1c ) and insoluble in lower-ionic-strength solutions. This construct was particularly amenable for structural and biochemical studies, presumably because it lacked the proline-rich linker region present in the fulllength protein.
Crystal structures of IST1 NTD
We crystallized IST1 NTD under high-ionic-strength conditions and determined the structure in space groups P2 1 (1.8-Å resolution) and P4 3 2 1 2 (2.6-Å resolution) ( Table 1 and Supplementary Fig. 1 ). The structures were similar, and the higher-resolution P2 1 structure is described here. IST1 NTD is composed of eight helices that pack to create a flat, elongated structure, with overall dimensions of 21 Â 30 Â 60 Å (Fig. 2a ). The two longest helices, a1 and a2, form a helical hairpin that packs against the smaller a3 and a4 helices to create an asymmetric four-helix bundle (termed the 'core'). Beyond the core, the segment between helices a4 and a5 forms a flap that tracks along the length of the molecule, packing against the a2-a3 edge. The flap contains two short helices, designated aA and aB to maintain a consistent numbering scheme for conserved ESCRT-III helices. Helix a5 packs perpendicularly across helices a1 and a2 near the closed end of the hairpin and is termed the 'autoinhibitory helix' . A final turn takes the polypeptide across the hairpin loop and into a6, which projects away from the core. This helix was seen in only the P2 1 crystal form, where it is stabilized by lattice contacts. As discussed below, the IST1 NTD structure seems to represent a closed, autoinhibited ESCRT-III conformation in which the flap and autoinhibitory helix fold against the core to prevent higher-order interactions. IST1 NTD bears an unexpected resemblance to the published CHMP3 8-183 structure 16 (Fig. 2a-c) , and the four helices of the IST1 NTD core superimpose with the first four helices of CHMP3 with an r.m.s. deviation of 2.4 Å (128 Ca positions). Muziol et al. noted that the a1 edge of CHMP3 is distinctly cationic and proposed that this surface binds membranes 16 . The equivalent IST1 surface is also basic, although the a3-a4 face is even more so ( Fig. 2d-f ).
In addition to their similar core structures, the autoinhibitory a5 helices of CHMP3 and IST1 NTD sit in equivalent positions ( Fig. 2a -c, a5, orange). Thus, all of the ordered helices in the CHMP3 structure have analogs in IST1 NTD . However, the assigned connectivity of the autoinhibitory helices differ between the two structures because this helix is connected in cis to the IST1 NTD core via the flap segment, whereas it was assigned to an adjacent molecule in the CHMP3 8-183 lattice 16 . Muziol et al. noted, however, that the CHMP3 8-183 connectivity could not be defined unambiguously owing to a lack of visible electron density for the flap region 16 . We therefore speculate that the CHMP3 8-183 connectivity may actually match that of IST1 NTD and that the CHMP3 8-183 structure may also represent a closed conformation.
Crystal structures of CHMP3
The CHMP3 construct lacked the final 39 CHMP3 residues, which may have favored an open conformation 16 . We therefore attempted to remove this ambiguity by crystallizing both the fulllength monomeric CHMP3 1-222 protein and a slightly truncated CHMP3 protein. Both proteins crystallized isomorphously in space group P2 1 , but CHMP3 8-222 diffracted to slightly higher resolution (4.0 Å ), and this structure is therefore reported ( Fig. 2c and Table 1 ). We determined the CHMP3 8-222 structure by molecular replacement, using the core of CHMP3 8-183 as a search model, and then subjected the structure to rigid body refinement. Discernible features beyond the search model were limited, but the structure solution is supported by the molecular replacement statistics (see Online Methods) and by unbiased electron density maps (Supplementary Fig. 2 ). In addition to the four core helices, density for the autoinhibitory helix was evident in unbiased electron density maps, particularly for one of the two independent molecules in the asymmetric unit ( Supplementary Fig. 2c,d ). Although the connectivity between a4 and a5 was not defined by experimental electron density, a5 seems to sit in the same position in both the CHMP3 and the CHMP3 8-222 structures, despite different crystal packing interactions in the two lattices. We have connected a4 and a5 in cis rather than in trans to create a structure with the same topology as IST1 NTD , and this assignment is consistent with biochemical analyses described below. Finally, we reasoned that a construct corresponding to the CHMP3 core alone could not adopt an autoinhibited conformation and might therefore reveal authentic protein-protein interactions used for ESCRT-III assembly. We crystallized the CHMP3 core construct (CHMP3 1-150 ) in space group P6 1 and solved the structure by molecular replacement (3.7-Å resolution; Table 1 and Supplementary  Fig. 2b ). As expected, the CHMP3 1-150 core was similar to the cores of the other CHMP3 and IST1 NTD structures, although, as described below, the lattice interactions were unique.
Crystal packing interactions
We analyzed lattice contacts in the different IST1 and CHMP3 crystal structures to determine whether they were strong candidates for authentic interactions used in ESCRT-III protein assembly (see Supplementary Figure 3 for a complete catalog of the different lattice interactions). Overall, there are no compelling reasons to believe that any of the various crystal contacts represent authentic assembly interfaces. Moreover, both of our CHMP3 structures lacked the 'side-to-side' dimer interface seen in the CHMP3 8-183 structure 16 and postulated as a possible ESCRT-III assembly interface 6, 7 .
Two of the new CHMP3 interfaces merit comment because they are mediated by a conserved, exposed hydrophobic surface on the closed 'tip' of the a1-a2 hairpin. In the CHMP 8-222 structure, two adjacent molecules associate through a small (359 Å 2 ) two-fold symmetric 'tipto-tip' dimer interface ( Fig. 3a,b) . A similar tip-to-tip interface was also present in the CHMP3 8-183 lattice 16 , and this is the only interface that has been seen in more than one crystal form. a b e c d CHMP3 dimeric contacts CHMP3 1-150 3 1 contacts 90°F igure 3 CHMP3 crystal packing interactions. (a) Overlay of the cores of the tip-to-tip dimers in the crystal lattices of CHMP3 (orange) 16 and CHMP3 (blue and green). The upper subunits were aligned, and the lower subunits diverge owing to small differences in their tip-totip interfaces. (b) Detailed expansion of the boxed region of CHMP3 shown in a. Most side chains conformations are shown as defined in the CHMP3 search model, with some minor adjustments to avoid clashes. Precise description of these side chain conformations is not possible at current resolutions. (c) Subunit packing down the 3 1 screw axis of the CHMP3 1-150 crystal lattice, with a single CHMP3 1-150 molecule highlighted in blue. (d) Same assembly as in c but viewed perpendicularly to the 3 1 screw axis. A different type of tip-to-tip interaction is present in the CHMP3 1-150 lattice. In this case, the interaction lacks two-fold rotational symmetry and instead follows a crystallographic 3 1 screw axis that creates an infinite CHMP3 1-150 filament with interfaces on both sides of the tip ( Fig. 3c-e ). The yeast homolog of CHMP3 (Vps24p) can assemble into three-stranded filaments in vitro 7 , although the relationship between the Vps24p filaments and the crystallographic CHMP3 filaments remains to be determined. In summary, the crystal packing interactions in our IST1 and CHMP3 structures do not obviously correspond to authentic biological interfaces, but do reinforce the idea that the exposed hydrophobic surface located at the tip of the helix 1helix 2 loop is a preferred site for protein-protein interactions 6, 7, 16 .
IST1 NTD binds CHMP1 proteins
Many ESCRT-III proteins bind one another, and previous studies have shown that the N-terminal domain of IST1 binds preferentially to the C-terminal region of the CHMP1 subset of ESCRT-III proteins [11] [12] [13] [14] .
To map the IST1 binding surface more precisely, we created an ensemble of IST1 proteins with point mutations at conserved, surface-exposed residues and tested them for CHMP1A and CHMP1B interactions using: (i) immunoprecipitation reactions in 293T cells (not shown), (ii) glutathione S-transferase (GST) pull-down experiments with recombinant proteins (not shown) and (iii) biosensor binding experiments in which pure recombinant CHMP1B bound immobilized GST-IST1 NTD (Fig. 4) .
CHMP1B bound wild-type IST1 NTD with an estimated dissociation constant of 22 ± 2 mM ( Fig. 4a,b ). CHMP1B binding was unaltered by most mutations tested, including mutations within the closed tip of the a1-a2 hairpin (for example, E39A, Y43D, K48D, R51D, I54D and R55D) and in the IST1 NTD surface that corresponded to the side-toside dimer interface seen in the crystal structure of CHMP3 and included the signature 73-ELYCEL-78 motif (for example, E70A, L74R, Y75A and L78R). However, one mutation along helix 2 (E67A) reduced CHMP1B binding in the immunoprecipitation and pull-down experiments and lowered the CHMP1B binding affinity six-fold in the biosensor binding assay, suggesting that this residue contributed to the CHMP1B binding site. We therefore tested mutations in adjacent surface-exposed residues to identify the CHMP1B binding site more precisely. Three IST1 mutants bound CHMP1B weakly (reductions in affinity of more than eight-fold; IST1 Y64D , IST1 Y165A and IST1 E168R ), three bound CHMP1B with intermediate affinities (two-to eight-fold reductions; IST1 D63A , IST1 E67A and IST1 R164D ) and one still bound strongly to CHMP1B (IST1 E163R ; data not shown).
Given the proximity of the apparent CHMP1B binding site to the IST1 autoinhibitory helix a5, we also tested the effects of a series of IST1 mutations predicted to destabilize the a5-core interface (V56D, I60D, L166D and I169D). All of these IST1 mutations blocked CHMP1B binding entirely (data not shown), indicating that CHMP1B binds the closed conformation of IST1 NTD seen in the crystal structures. As summarized in Figure 4c , mutations that inhibited CHMP1B binding clustered within or near a groove created by packing of autoinhibitory helix a5 against core helix a2. The groove features a pair of exposed tyrosine residues (Tyr64 and Tyr165) that probably contribute to CHMP1B binding.
The IST1-CHMP1B interactions function in cytokinesis
To determine whether CHMP1 binding was necessary for IST1 cytokinesis function(s), we tested whether IST1 mutations that impaired CHMP1B binding also inhibited abscission. Depletion of endogenous IST1 increased the percentage of HeLa cells with visible midbodies from 4 ± 1% to 20 ± 3% (Fig. 5a, compare lanes 1 and 2, and Fig. 5b , compare image above left with image above middle), and this midbody arrest defect was largely (but not entirely) rescued by re-expression of a wild-type, small interfering RNA (siRNA)resistant IST1 construct (8 ± 2% ; Fig. 5a, lane 3, and Fig. 5b , above right) 11 . Midbody arrest was also corrected by an IST1 protein with a mutation in the tip of the a1-a2 hairpin that retained strong (S) CHMP1B binding (IST1 R51D , 8 ± 1% ; Fig. 5a , lane 4, and Fig. 5b , below left). In contrast, three weakly binding IST1 mutants failed to rescue midbody arrest (18-21%; Fig. 5a , lanes 7-9, and Fig. 5b , images below middle and below right). Point mutations within the a5-core interface that blocked CHMP1B binding also blocked rescue of the midbody arrest defect. However, these mutant proteins partitioned almost exclusively into the insoluble, membrane-bound cellular fractions, and their failure to support abscission may therefore reflect either aberrant CHMP1 binding or IST1 protein mislocalization ( Supplementary Fig. 4 and Supplementary Discussion). Finally, two IST1 mutants with intermediate (I) CHMP1B binding affinities rescued midbody arrest to an intermediate extent (12-13%; Fig. 5a , lanes 5 and 6). Hence, there was an excellent correlation between the ability of different IST1 constructs to bind CHMP1B in vitro and to function in abscission, indicating that CHMP1 binding is required for IST1 abscission function(s). IST1 NTD and CHMP1B form homopolymeric helices in vitro CHMP3 can co-polymerize with truncated CHMP2A proteins to form helical tubes 50 nm in diameter in vitro 6 . As noted above, both IST1 and IST1 NTD became insoluble under low-ionic-strength conditions, and we therefore tested whether these proteins assembled into regular structures. We initially surveyed assembly conditions using light scattering to follow complex formation. Monomeric IST1 NTD spontaneously polymerized into high-molecular-weight complexes that strongly scattered light at 330 nm when the protein was diluted from a high-salt buffer (350 mM NaCl) into a low-salt buffer (100 mM NaCl) (Fig. 6a) . In contrast, IST1 NTD did not scatter light when diluted into an otherwise equivalent high-salt buffer (350 mM NaCl).
EM analyses revealed that the light-scattering IST1 NTD assemblies were large tubular structures with diameters of B700 nm (Fig. 6b, lower left images) . The tubes seemed to be open along one edge and may therefore be curled sheets rather than fully closed (a) Assembly of wild-type (WT) IST1 NTD or three different IST1 NTD mutants with the designated amino acid substitutions at the tip of the a1-a2 hairpin (mutated residues are underlined in Figure 4c ). IST1 NTD proteins were diluted from concentrated protein stocks in high-salt buffers to final concentrations of 62 mM. Salt concentrations in the assembly buffers are provided in the inset key and protein assembly was followed by light scattering at 330 nm. (b) TEM images of a subset of the wild-type and mutant IST1 NTD assembly reactions from a. Note that IST1 NTD assembled only under low-salt conditions (compare upper and middle left images) and that IST1 NTD proteins with different point mutations at the tip of the a1-a2 hairpin did not assemble in either high-salt (not shown) or low-salt conditions (right). An expanded view of a single IST1 NTD tube is shown in the lower left image. Scale bars, 500 nm. (c) TEM images of CHMP1B tubes assembled under low-salt conditions. A field of tubes is shown at left and an expanded view of a single CHMP1B tube is shown at right. Scale bars, 500 nm. helices. Lattice lines were evident in some assemblies, and the clearest lattice spacing was B440 Å , which presumably represents a supermolecular spacing because the maximal length of a single IST1 NTD molecule is only B60 Å . As noted above, CHMP3 interactions can be mediated by various different kinds of tip-totip interactions 6, 7 (Fig. 3) . A series of three point mutations in the analogous IST1 surface (Y43D, R51D and I54D) also inhibited IST1 NTD polymerization ( Fig. 6a,b , right) (see Supplementary  Fig. 5 for ESCRT-III protein alignments). IST1 NTD assembly therefore probably also requires some type of tip-to-tip interaction.
We also attempted to test whether IST1 NTD and CHMP1B could copolymerize in a manner similar to the CHMP2A 9-161 -CHMP3 pair 6 . However, controls for these experiments revealed that pure recombinant CHMP1B alone polymerized into helical tubes when diluted into lowsalt buffers, even in the absence of IST1 NTD (Fig. 6c) . CHMP1B tubes were of intermediate size (B230 nm in diameter), seemed to be fully closed and had visible lattice spacing of B420 Å , similar to the lattice spacing in the IST1 NTD tubes. Thus, both IST1 NTD and CHMP1B, as for CHMP2A-CHMP3 (ref. 6) , form tubular structures in vitro, and the ability to assemble into helical tubes therefore seems to be a property common to many ESCRT-III core domains. However, the IST1 and CHMP1B tubes were homopolymeric, and they were substantially larger than those formed by CHMP2A-CHMP3 heteropolymers 6 .
CHMP3 a1-a2 hairpin tip binds CHMP2A As with the IST1-CHMP1 pair, CHMP2A and CHMP3 bind one another preferentially. To investigate this interaction further, we used GST pull-down assays to test for binary interactions between CHMP2A and GST-CHMP3 (Fig. 7a,b) . We performed these experiments at low protein concentrations where higher-order assemblies were not detectable (35 mM CHMP2A, B7 mM GST-CHMP3). CHMP2A protein bound GST-CHMP3 (Fig. 7b, lane 3) but did not bind a matrix control (lane 2). CHMP2A also bound the truncated GST-CHMP3 1-150 protein (lane 4), indicating that CHMP2A interacted with the CHMP3 core and that the binary interaction was not strongly affected by removal of the terminal CHMP3 autoinhibitory sequences. In contrast, a double point mutation (V59D V62D) that disrupted the exposed hydrophobic surface on one side of the tip of the CHMP3 a1-a2 hairpin eliminated CHMP2A binding (lane 5). These data suggest that CHMP2A and CHMP3 interact through a tipto-tip interaction and demonstrate that the binary CHMP2A-CHMP3 and IST1-CHMP1B pairs interact via different binding surfaces, and therefore form structurally distinct complexes.
Autoinhibitory helix inhibits CHMP3 polymerization
Comparative analyses of the IST1 NTD , CHMP3 and CHMP3 structures suggested a model for ESCRT-III autoinhibition in which the a5 helix and flap elements fold back against the protein core to prevent higher-order assembly. We tested this idea by introducing destabilizing mutations within the a5-core interface of the full-length CHMP3 protein and testing their effects on CHMP2A co-assembly. Although the full-length CHMP2A and CHMP3 proteins bind one another, these two proteins do not readily form higher-order helical assemblies 6 (Fig. 7c,i) . In contrast, a CHMP3 1-150 protein that lacked the flap and autoinhibitory helix readily co-polymerized with CHMP2A to form long, regular helical tubes (Fig. 7c ,ii, positive control). As CHMP2A forms binary complexes with both CHMP3 and CHMP3 , these experiments imply that CHMP3 residues 151-222 inhibit additional interaction(s) required for higherorder assembly.
To examine the mechanism of CHMP3 autoinhibition, we mixed full-length CHMP2A with full-length CHMP3 proteins that contained mutations on either side of the core-a5 interface (CHMP3 V48D A64D and CHMP3 I168D L169D , Fig. 7a ). Both sets of mutations activated CHMP3 for assembly, as reflected in the formation of numerous rings, tubes and cones (Fig. 7c,iii,iv) . The tubes were similar in diameter to those formed in the CHMP2A-CHMP3 1-150 control reaction (B50 nm) but were typically shorter, possibly because the point mutations activated CHMP3 proteins less fully than removal of the entire autoinhibitory region.
We also tested whether the binary CHMP2A-CHMP3 interface detected at low protein concentrations was required for higher-order assembly. As expected, mutations on either side of the CHMP3 autoinhibitory interface did not substantially affect CHMP2A binding to GST-CHMP3 (CHMP3 V48D A64D and CHMP3 I168D L169D ; Fig. 7b,  lanes 6 and 7) . However, a CHMP3 protein carrying mutations in both the tip and autoinhibitory interfaces (CHMP3 V59D V62D I168D L169D ) could neither bind CHMP2A in the GST pull-down assay (Fig. 7b,  lane 8) nor assemble into helical tubes (Fig. 7c,v) . These experiments imply that tip-to-tip interactions contribute to CHMP2-CHMP3 co-assembly, in good agreement with a previous study 6 .
Mutations in the autoinhibitory helix activate CHMP3 in vivo
Although co-expression of full-length CHMP3 has only minimal effects on HIV-1 budding, truncated CHMP3 constructs lacking the C-terminal autoinhibitory elements potently inhibit virus budding, presumably because the activated protein sequesters itself and other ESCRT-III proteins on cellular membranes 20 . Inhibition of HIV release therefore provides a sensitive assay for CHMP3 activation in vivo. We used this system to examine whether mutations in the a5-core interface also activate CHMP3 in vivo. Overexpression of full-length CHMP3 together with an HIV-1 vector system in 293T cells had little effect on the release of viral particles, as measured by the levels of virion-associated CA proteins released (Fig. 8, image 3, compare lanes  1 and 2) or by viral titers (Fig. 8, image 4, compare lanes 1 and 2) . In contrast, HIV release and infectivity were potently inhibited by coexpression of a CHMP3 protein that lacked the autoinhibitory region entirely (CHMP3 1-150 , positive control, compare lanes 2 and 3, showing a 4250-fold infectivity reduction). In the actual experiment, two different CHMP3 proteins with point mutations within the a5-core interface (CHMP3 I168D L169D and CHMP3 V48D I168D L169D ) reduced HIV vector release and infectivity by 1.7-fold and 3-fold, respectively (compare lanes 4 and 5 to lane 2). Western blots confirmed that the full-length CHMP3 proteins and viral Gag proteins and proteolytic processing products were expressed at similar levels (images 1 and 2, respectively). Thus, point mutations in the a5-core interface enhanced the ability of CHMP3 proteins to inhibit HIV-1 budding in vivo, although this enhancement was much weaker than that seen upon deletion of the entire autoinhibitory region. We presume that the weaker effects seen for the point mutants reflects either incomplete activation and/or their ability to interact with VPS4, which will reduce their propensity to become 'trapped' on membranes, as compared to CHMP3 (which lacks a terminal VPS4 binding site).
DISCUSSION
Our studies have unexpectedly revealed that the N-terminal domain of IST1 contains an asymmetric four-helix bundle that closely resembles the core of the ESCRT-III protein CHMP3 (Fig. 2) . As is true for other ESCRT-III proteins, IST1 (i) localizes to midbodies and functions in cytokinesis 11, 14 and MVB vesicle sorting 12, 13 , (ii) binds preferentially to another subset of ESCRT-III proteins (the CHMP1 proteins) [11] [12] [13] [14] , (iii) contains MIM elements near its C terminus that can bind VPS4 and LIP5 MIT domains 11, 14 and (iv) can self-assemble into tubular structures in vitro (Fig. 6) . Thus, despite its larger size and primary sequence divergence, IST1 is an ESCRT-III protein family member. Despite these similarities, there are also important differences between IST1 and CHMP3, particularly in the binary interactions that they make with their CHMP1 and CHMP2 binding partners. Our mutational analyses mapped the CHMP1 binding site to a groove formed by the autoinhibitory a5 helix and the core a2 helix of IST1 NTD (Fig. 4) . CHMP1B binding was also inhibited by mutations expected to favor the (hypothetical) open IST1 NTD conformation, implying that CHMP1 binds the closed conformation seen in our IST1 NTD crystal structures (Fig. 2) . IST1 mutations that blocked CHMP1B binding also prevented IST1 from functioning in abscission, implying that these two proteins must act together during this final stage of cytokinesis (Fig. 5) . In contrast, binary interactions between CHMP2 and CHMP3 were not inhibited by mutations that displaced or even removed the a5 helix entirely (Fig. 7) . This interaction was sensitive to mutations at the tip of the a1-a2 hairpin, however, suggesting that, unlike IST1 and CHMP1B, CHMP2 and CHMP3 probably interact through some sort of a tip-to-tip interaction (Fig. 7) .
In vitro assemblies formed by ESCRT-III proteins include filaments, rings, cones, curled sheets and tubes 6, 7 (Figs. 6b,c and 7c) . At present, we do not know which (if any) of these different in vitro assemblies mimic different ESCRT-III assemblies formed in vivo. As noted previously [5] [6] [7] , however, filaments, rings and/or tubes could correspond to 'collars' within the necks of budding particles, and tapered tubes or spiraling cones could provide a mechanism for closing the neck during budding 6 (Fig. 7c, structure type 3) . Although the precise molecular interactions that mediate higher-order ESCRT-III assembly remain to be determined, both IST1 NTD and CHMP2-CHMP3 assemblies are inhibited by point mutations within the conserved, exposed hydrophobic surface located at the tip of the a1-a2 hairpin (Figs. 6b and  7c ), suggesting that some type of tip-mediated interface forms within both assemblies. Two distinct types of homopolymeric ESCRT-III tipto-tip interactions have now been seen crystallographically 16 (Fig. 3) , and a third type was inferred from cryo-EM studies of helical yeast Vps24 (CHMP3) assemblies 7 . Thus, the conserved hydrophobic surface at the tip of ESCRT-III proteins is a preferred interaction site, although it is not yet clear which, if any, of the tip-to-tip interactions characterized to date represent biologically relevant interactions. We also note that, although the IST1 R51D tip mutation inhibits IST1 assembly (Fig. 6a,b) it does not block the ability of IST1 to function in cytokinesis ( Fig. 5) , implying that there are different requirements for IST1 assembly in vitro and abscission function in vivo. Finally, in addition to tip contacts, at least one more protein-protein interface is required to create two-dimensional surfaces in helices or sheets. These secondary interaction(s) are disfavored by C-terminal autoinhibitory interactions (ref. 6 and this work) and may correspond to one of the several different kinds of higher-order packing interactions that have been proposed on the basis of cryo-EM analyses of helical ESCRT-III protein assemblies 6, 7 .
Our IST1 NTD structure revealed that the downstream flap and autoinhibitory helix can fold back against the ESCRT-III core, and this topology was unambiguously established by high-quality electron density throughout the flap region ( Fig. 2 and Supplementary Fig. 1 ). Analogous models can be built for the CHMP3 and CHMP3 structures, although in those cases the connectivity has not been established unambiguously. Nevertheless, we suggest that all of these structures probably correspond to the closed, autoinhibited ESCRT-III conformation, for several reasons: (i) both IST1 NTD and CHMP3 are monomers in solution under the conditions used for crystallization (although IST1 NTD polymerizes under low-salt conditions) ( Fig. 1) ; (ii) IST1 is redistributed into the insoluble membrane-bound, assembled fractions of cellular extracts by mutations that disrupt core packing of the autoinhibitory elements ( Supplementary Fig. 4) ; (iii) CHMP3 and CHMP2A can be activated for co-assembly by deletions that remove the autoinhibitory helices from CHMP2A 6 or CHMP3, or by point mutations that destabilize packing of the CHMP3 autoinhibitory helix against the core (Fig. 7) ; (iv) mutations that remove the autoinhibitory helix or destabilize its core packing interactions render CHMP3 a dominant inhibitor of HIV-1 budding 17, 20 (Fig. 8) . Nevertheless, there is also good evidence that additional contacts beyond those visualized in our IST1 NTD or CHMP3 structures help to stabilize the closed CHMP3 conformation even further, because point mutations in the autoinhibitory helix-core interface do not activate CHMP3 to the same extent as does deletion of the entire autoinhibitory region ( Figs. 7c and 8) , and because short C-terminal deletions downstream of the autoinhibitory a5 helix can also enhance ESCRT-III membrane binding and inhibition of HIV-1 budding, albeit to a lesser extent than deletions that include a5 (refs. 17,20) . These observations indicate that the terminal ESCRT-III helix 6 (and possibly also flap sequences) make energetically important contacts that favor the closed ESCRT-III conformation.
In summary, many ESCRT-III proteins can adopt two distinct conformational states 6, [16] [17] [18] [19] [20] [21] , and our studies provide a molecular model for the closed, monomeric state adopted by ESCRT-III proteins when they are distributed throughout the cytoplasm (or loosely associated with nonspecific membranes) 34 . Primary sequence and secondary-structure analyses indicate that all ESCRT-III proteins have analogous a5 helices in equivalent positions, and the mechanism of autoinhibition described here is probably quite general (Supplementary Fig. 5a ). Surrounding elements can vary substantially in sequence, length and secondary structure, however, and they probably mediate various protein-protein interactions 33 . Notably, these different protein-protein interactions can be enhanced, inhibited or unchanged by mutations that favor the open states of various ESCRT-III proteins (for example, refs. 21, 22, 28, 33) . Thus, changes in protein-protein and protein-membrane interactions that accompany ESCRT-III activation and assembly are likely to reflect the conformational changes described here, coupled with avidity effects created by the assembly of oligomeric ESCRT-III protein arrays.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Accession Codes. Protein Data Bank: Coordinates and structure factor amplitudes have been deposited for the two IST1 NTD crystal forms (3FRR and 3FRS), CHMP (3FRT) and CHMP3 1-150 (3FRV). Supplementary Tables 1 and 2. Protein expression and purification. We expressed IST1 and CHMP proteins in Escherichia coli with N-terminal GST-affinity tags. Protein expression, purification and tag removal are described in the Supplementary Methods.
ONLINE METHODS
Expression vectors and antibodies. Vectors and antibodies are summarized in
Equilibrium sedimentation analyses. We centrifuged purified CHMP3, CHMP3 and IST1 NTD in 10 mM Tris-HCl pH 8.0, 100 mM NaCl (CHMP3 proteins) or 50 mM Tris-HCl pH 7.0, 350 mM NaCl and 1 mM DTT (IST1 NTD ) at 4 1C in an Optima XL-A centrifuge (Beckman). Initial protein concentrations are given in Figure 1a -c. Data were collected after equilibrium was reached at two speeds (20,000 r.p.m. and 24,000 r.p.m.) in a Beckman An-60 Ti rotor, and the molecular masses were determined from the resulting six data sets for each protein by globally fitting to single ideal species models using the nonlinear least-squares algorithms in the Heteroanalysis software 36 . Protein partial specific volumes and solvent densities were calculated with the program SEDNTERP (version 1.09) 37 .
Protein crystallization and data collection. We crystallized IST1 NTD , CHMP3 and CHMP3 1-150 by vapor diffusion at 13 1C. IST1 NTD crystals grew from a 12 mg ml -1 solution in gel filtration buffer. Crystal form I (diamond-shaped morphology, P4 3 2 1 2, 1 molecule per asymmetric unit) grew in 1-3 d by simple dehydration of a 2-ml drop. Crystals were cryoprotected by passage through silica oil, suspended in a nylon loop and plunged into liquid nitrogen. Crystal form II (rods and plates, P2 1 , 1 molecule per asymmetric unit) grew from a 1:1 (v/v) mixture of protein and well solution (180 mM KCl, 50 mM HEPES pH 7.6, 35% pentaethritol propexylate and 7% (v/v) ethylene glycol). Crystals were cryo-cooled directly without solution modification. Native data for both crystal forms were collected on a Rigaku Micromax 007HF rotating anode generator equipped with VeriMax-HR optics.
CHMP3 crystals (flat plates, P2 1 , 2 molecules per asymmetric unit) grew from a 1:2 (v/v) mixture of protein (30 mg ml -1 in gel filtration buffer) and well solution (10-22% PEG 6000 and 0.1M Na-HEPES pH 7.0-8.0). Data were collected at SSRL beamline 11-1. CHMP3 1-150 crystals (hexagonal rods, P6 1 ) grew from a 1:1 (v/v) mixture of protein (22 mg ml À1 in gel filtration buffer) and well solution (16% (v/v) PEG 3350, 0.1 M Na HEPES pH 7.0-8.0, 200 mM proline). Data were collected on a rotating anode generator. Despite extensive effort, we were unable to collect better data at the synchrotron. Data were indexed and scaled with the program HKL2000 (ref. 38) ( Table 1) .
Structure determinations. We collected three-wavelength MAD data from selenomethionine-substituted IST1 NTD at SSRL beamline 9-1 to 3.4 Å . Three of the six potential selenium sites were identified using SOLVE 39 , and the resulting 4.0-Å phases were solvent flattened and extended to 2.6-Å resolution using the native data and the program DM 40 . The four core helices (a1-a4) were built using O 41 , and this partial model was used for molecular replacement determination of the higher-resolution form II crystal structure using PHA-SER 42 . The models were completed with COOT 43 , refined with REFMAC5 (ref. 44 ) and analyzed using programs within the CCP4 suite 45 . The similar IST1 NTD structures in the two crystal forms overlapped with an r.m.s. deviation of 1.25 Å on Ca atoms 12-170.
We determined both CHMP3 structures by molecular replacement using the published CHMP3 8-183 structure (PDB 2GD5) 16 as the search model. The correctness of the solutions is supported by PHASER 42 Z-scores of 9.1 (CHMP3 ) and 8.6 (CHMP3 1-150 ) and by the appearance of electron density when portions of the search model were omitted from the molecular replacement calculation ( Supplementary Fig. 2 ). Both structures are hampered by low resolution and a correspondingly low number of unique reflections. R free sets of 5% contain too few reflections (B120) to be statistically useful. An optimal strategy was therefore determined by considering R free values from multiple refinement runs, each starting from the same molecular replacement solution and with a different small number (B200) of reflections in the test set. This indicated that the best results were obtained using rigid-body refinement in PHENIX 46 with each helix treated as a rigid unit. This approach was therefore applied to the starting molecular replacement solution but using all of the reflections in the calculation (no test set).
Biosensor binding assays. We used BIACORE2000 and BIACORE3000 instruments (GE Healthcare) to measure the binding of pure recombinant CHMP1B to immobilized GST-IST1 NTD proteins captured from E. coli extracts 28 , as described in Supplementary Methods. IST1 depletion and rescue experiments. We transfected HeLa-M cells with IST1 expression vectors (1 mg per well, using Lipofectamine 2000, Invitrogen) and siRNA (20nM, Lipofectamin RNAi MAX, Invitrogen) following the time course: t ¼ 0, seed cells in DMEM and 10% (v/v) FCS (six-well plates, 4 Â 10 5 cells per well); t ¼ 24 h, add IST1 expression vector; t ¼ 32 h, change media and add IST1 vector; t ¼ 44 h, trypsinize and reseed cells on 18-mm glass cover slips for immunofluorescence analyses (3 Â 10 4 cells per cover slip) and in sixwell plates for western blotting (3 Â 10 5 cells per well); t ¼ 56 h, change media and add siRNA; t ¼ 68 h, change media and add siRNA; t ¼ 94 h, fix or harvest cells and analyze.
Direct visualization of cytokinesis defects. We fixed transfected HeLa-M cells with 4% (v/v) paraformaldehyde and stained with SYTOX Green (Invitrogen) and with mouse anti-a-tubulin and a secondary Alexa 594-conjugated goat anti-mouse antibody. We scored midbody arrest manually for Z3 blinded sets of 200 cells by direct visualization using fluorescence microscopy.
ESCRT-III assembly reactions. Assembly conditions for CHMP2A and CHMP3, IST1 NTD , and CHMP1B proteins are provided in the Supplementary Methods.
Transmission electron microscopy. We analyzed assembly reactions using TEM with negative staining. Carbon-coated grids were placed on aliquots of each assembly reaction (7 ml, 90 s), washed with 3-4 drops of 0.1 M KCl, stained with 3-4 drops of 4% (v/v) uranyl acetate, air dried and imaged (Hitachi 7100 TEM).
GST pull-down assays. We tested the binding of pure recombinant CHMP2A proteins to various GST-CHMP3 proteins as described in the Supplementary Methods.
HIV-1 vector release and infectivity. We co-transfected 293T cells with vectors expressing CHMP3-Myc and HIV-1 and harvested supernatants and cells after 24 h. Western blotting was used to analyze cellular proteins and virions pelleted through 20% sucrose cushion and HeLa-M cell transduction to measure vector titers. Full details are provided in Supplementary Methods.
